Related Experiment Video

Updated: Jun 4, 2026

Nine-Grid Area Division Method: A New Ideal Bone Puncture Region for Percutaneous Vertebroplasty in Lumbar Spine
09:29

Nine-Grid Area Division Method: A New Ideal Bone Puncture Region for Percutaneous Vertebroplasty in Lumbar Spine

Published on: August 9, 2024

Kyphoplasty in cancer: an encouraging step

David Schiff1, Mary E Jensen

  • 1Neuro-Oncology Center, University of Virginia Health Science Center, Charlottesville, VA, USA. davidschiff @virginia.edu

The Lancet. Oncology
|February 22, 2011
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Modified Posterior Vertebral Column Resection for Patients with Thoracolumbar Kyphotic Deformity
06:45

Modified Posterior Vertebral Column Resection for Patients with Thoracolumbar Kyphotic Deformity

Published on: September 16, 2022

Related Experiment Videos

Last Updated: Jun 4, 2026

Nine-Grid Area Division Method: A New Ideal Bone Puncture Region for Percutaneous Vertebroplasty in Lumbar Spine
09:29

Nine-Grid Area Division Method: A New Ideal Bone Puncture Region for Percutaneous Vertebroplasty in Lumbar Spine

Published on: August 9, 2024

Modified Posterior Vertebral Column Resection for Patients with Thoracolumbar Kyphotic Deformity
06:45

Modified Posterior Vertebral Column Resection for Patients with Thoracolumbar Kyphotic Deformity

Published on: September 16, 2022

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

Therapeutic delivery of microRNAs discovered to target deregulated glioblastoma pathways inhibits tumor growth in mice.

The Journal of clinical investigation·2026

Microenvironment T-Type calcium channels regulate neuronal and glial processes in tumor cells to promote glioblastoma growth.

Neuro-oncology·2026

Tumor Growth Rate (TGR) Analysis Predicts Survival in a Multicenter Phase II Study of the PARP Inhibitor Pamiparib (BGB-290) with Temozolomide in Recurrent IDH-Mutant Gliomas (ABTC-1801).

AJNR. American journal of neuroradiology·2026

Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Evaluation of Regorafenib in Newly Diagnosed and Recurrent Glioblastoma: GBM AGILE Phase II/III Bayesian Randomized Platform Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Practical Management of Headaches in Patients With Primary and Secondary Brain Tumors.

Journal of pain and symptom management·2026

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.

The Lancet. Oncology·2026

Consensus statements from the first Gynecologic Cancer InterGroup Cervical Cancer Consensus Conference in Clinical Research.

The Lancet. Oncology·2026

Advancing oncology education in low-income and middle-income African settings: global insights for local action.

The Lancet. Oncology·2026

Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle-invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial.

The Lancet. Oncology·2026

Postmastectomy chest wall radiotherapy for breast cancer (SUPREMO): 5-year quality-of-life results from a randomised, controlled, phase 3 trial.

The Lancet. Oncology·2026

Addition of irinotecan to chemoradiotherapy as preoperative treatment for locally advanced rectal cancer (ARISTOTLE): a multicentre, open-label, phase 3, randomised controlled trial.

The Lancet. Oncology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us